As the individualized needs of patients are further prioritized in Parkinson disease care, the director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute shared her perspective on shared decision-making. [WATCH TIME: 4 minutes]
The head of the MS center at University Hospital Basel provided insight on the role of BTK inhibitors and how the multiple sclerosis community views the potential of neurofilament light as a key biomarker of neurodegeneration. [WATCH TIME: 3 minutes]
Recommendations from neurologists James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN for addressing acute exacerbation in patients with myasthenia gravis.
Two subject matter experts discuss cases where a thymectomy is appropriate for treating patients with myasthenia gravis.
The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed the current methods of prescribing rehabilitation and why a new digital tool can improve them going forward. [WATCH TIME: 3 minutes]
The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]
Neurology News Network for the week ending June 25, 2022. [WATCH TIME: 4 minutes]
The associate neurologist at Brigham and Women’s Hospital provided insight on the current state of promising targets in progressive MS and why anti-CD3 therapy might be a new consideration for future trials. [WATCH TIME: 2 minutes]
Expert neurologists emphasize the importance of conversations around patient lifestyle, mental health, and comorbid conditions as keys to improve care for MS.
Barry A. Hendin, MD; Regina Berkovich, MD, PhD; and Ahmed Z. Obeidat, MD, PhD, explore the role of biomarkers, precision medicine, and repair mechanisms to improve treatment of MS going forward.
Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review potential use of BTK inhibitors in the treatment of MS.
Kelly Knupp, MD, reviews available treatment options indicated for Dravet syndrome and shares her thoughts on the use of cannabidiol for patients.
Kelly Knupp, MD, leads a discussion on goals of treatment for patients who are earlier in their treatment journey.
The associate professor in the Department of Rehabilitation Medicine at NYU Langone provided insight on a recent study that utilized a novel digital tool to track the movement intensity of their stroke rehabilitation. [WATCH NOW: 4 minutes]
The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]
A trio of experts in multiple sclerosis exchanges their thoughts on the use of the sphingosine-1 phosphate modulating class of medicines in treating the disease. [WATCH TIME: 3 minutes]
Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, highlight novel administration routes for the management of OFF episodes in patients with Parkinson disease.
Laxman Bahroo, DO, examines the effectiveness of on-demand therapies to manage OFF episodes in Parkinson disease and highlights the importance of frequent monitoring and follow-up visits.
Rajesh Pahwa, MD, comments on the different routes of administration of on-demand therapies and medication absorption for the management of OFF episodes in Parkinson disease.
A trio of experts in multiple sclerosis exchanges their thoughts on the gains that have been made in the understanding of the progressive phases of the disease. [WATCH TIME: 3 minutes]
A trio of experts in multiple sclerosis exchanges their thoughts on the importance of patient-reported outcomes in the management of patients with the disease. [WATCH TIME: 3 minutes]
The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]
The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, share insights regarding acetylcholinesterase inhibitors and immunosuppressive therapy as first-line treatments for patients with myasthenia gravis.
Thought leaders offer practical advice on setting therapy goals for patients with myasthenia gravis, with an emphasis on patient inclusion.
The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]
Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]
The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]
Neurology News Network for the week ending June 18, 2022. [WATCH TIME: 3 minutes]
The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]
